|
1
|
Hehlmann R, Hochhaus A and Baccarani M;
European LeukemiaNet, : Chronic myeloid leukaemia. Lancet.
370:342–350. 20074 View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hoglund M, Sandin F and Simonsson B:
Epidemiology of chronic myeloid leukaemia: An update. Ann Hematol.
94 (Suppl 2):S241–S247. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ning L, Hu C, Lu P, Que Y, Zhu X and Li D:
Trends in disease burden of chronic myeloid leukemia at the global,
regional, and national levels: A population-based epidemiologic
study. Exp Hematol Oncol. 9:292020. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kurzrock R, Gutterman JU and Talpaz M: The
molecular genetics of philadelphia chromosome-positive leukemias. N
Engl J Med. 319:990–998. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Le Coutre P, Kreuzer KA, Na IK, Schwarz M,
Lupberger J, Holdhoff M, Baskaynak G, Gschaidmeier H, Platzbecker
U, Ehninger G, et al: Imatinib in philadelphia chromosome-positive
chronic phase cml patients: Molecular and cytogenetic response
rates and prediction of clinical outcome. Am J Hematol. 73:249–255.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Shah NP, Bhatia R, Altman JK, Amaya M,
Begna KH, Berman E, Chan O, Clements J, Collins RH, Curtin PT, et
al: Chronic myeloid leukemia, version 2.2024, nccn clinical
practice guidelines in oncology. J Natl Compr Canc Netw. 22:43–69.
2024. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Mahon FX and Etienne G: Deep molecular
response in chronic myeloid leukemia: The new goal of therapy? Clin
Cancer Res. 20:310–322. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Rinaldi I and Winston K: Chronic myeloid
leukemia, from pathophysiology to treatment-free remission: A
narrative literature review. J Blood Med. 14:261–277. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kennedy BJ: Hydroxyurea therapy in chronic
myelogenous leukemia. Cancer. 29:1052–1056. 1972. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Castagnetti F, Gugliotta G, Baccarani M,
Breccia M, Specchia G, Levato L, Abruzzese E, Rossi G, Iurlo A,
Martino B, et al: Differences among young adults, adults and
elderly chronic myeloid leukemia patients. Ann Oncol. 26:185–192.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Saussele S, Krauss MP, Hehlmann R,
Lauseker M, Proetel U, Kalmanti L, Hanfstein B, Fabarius A, Kraemer
D, Berdel WE, et al: Impact of comorbidities on overall survival in
patients with chronic myeloid leukemia: Results of the randomized
CML study IV. Blood. 126:42–49. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Cortes J, Talpaz M, O'Brien S, Giles F,
Beth Rios M, Shan J, Faderl S, Garcia-Manero G, Ferrajoli A, Wierda
W and Kantarjian H: Effects of age on prognosis with imatinib
mesylate therapy for patients with philadelphia chromosome-positive
chronic myelogenous leukemia. Cancer. 98:1105–1113. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kalmanti L, Saussele S, Lauseker M, Müller
MC, Dietz CT, Heinrich L, Hanfstein B, Proetel U, Fabarius A,
Krause SW, et al: Safety and efficacy of imatinib in cml over a
period of 10 years: Data from the randomized cml-study IV.
Leukemia. 29:1123–1132. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Adattini JA, Gross AS, Wong Doo N and
McLachlan AJ: Real-world efficacy and safety outcomes of imatinib
treatment in patients with chronic myeloid leukemia: An australian
experience. Pharmacol Res Perspect. 10:e010052022. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Gugliotta G, Castagnetti F, Palandri F,
Breccia M, Intermesoli T, Capucci A, Martino B, Pregno P, Rupoli S,
Ferrero D, et al: Frontline imatinib treatment of chronic myeloid
leukemia: No impact of age on outcome, a survey by the GIMEMA CML
working party. Blood. 117:5591–5599. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Cortes JE, Saglio G, Kantarjian HM,
Baccarani M, Mayer J, Boqué C, Shah NP, Chuah C, Casanova L,
Bradley-Garelik B, et al: Final 5-year study results of DASISION:
The dasatinib versus imatinib study in treatment-naive chronic
myeloid leukemia patients trial. J Clin Oncol. 34:2333–2340. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kantarjian HM, Hughes TP, Larson RA, Kim
DW, Issaragrisil S, le Coutre P, Etienne G, Boquimpani C, Pasquini
R, Clark RE, et al: Long-term outcomes with frontline nilotinib
versus imatinib in newly diagnosed chronic myeloid leukemia in
chronic phase: Enestnd 10-year analysis. Leukemia. 35:440–453.
2021. View Article : Google Scholar : PubMed/NCBI
|
